We evaluated clinical parameters associated with time to treatment failure (TTF) and real-world overall survival (rwOS).
In this review, we aim to provide a broad overview of the design and the recent advances of ADCs in breast cancer.
Antibody-drug conjugates in breast cancer: current evidence and future directions Read More »
The utility of capturing heterogeneity by circulating tumor DNA (ctDNA) genotyping combined with tissue analysis or applying it in a sequential manner remains uncertain.
This retrospective analysis investigated the impact of germline pathogenic variant (PV) status of BRCA1/2 and non-BRCA1/2 cancer predisposition genes on the outcomes of PENELOPE-B trial patients.
Recently, we reported the real-world effectiveness of palbociclib plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC) in Japan (NCT05399329). However, median overall survival (OS) was not reached because of limited follow-up (36 months). Here, we present follow-up data from this study, including real-world clinical outcomes and treatment patterns.
This review examines the successes and setbacks of ICI use in TNBC, offering a comprehensive overview of current practices and future directions. It emphasizes optimizing ICI timing, leveraging biomarkers, and integrating novel agents to refine treatment approaches for both metastatic and early-stage TNBC.
Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer Read More »
Targeted therapies have significantly improved outcomes, particularly for subtypes such as human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor (HR)-positive (HR+) BC. Key innovations include antibody single bond drug conjugates (ADCs) and next-generation endocrine therapies.
Novel Strategies in Breast Cancer Management: from Treatment to Long-term Remission Read More »
This study aimed to determine the extent to which so-called “reimbursed SDM consultations” are used in cancer treatment and to identify the characteristics of patients having these consultations using a nationwide database.
These findings underscore the importance of molecular subtyping in HR+/HER2+ breast cancer, offering a framework for developing precise and personalized treatment strategies.
This study investigates patients’ preferences regarding assessment of care needs and information provision.
This site is only for use by healthcare professionals.
By continuing to view this site you are confirming that you are a healthcare professional.
